ライフサイエンスコーパス: revascularized

1 ot impact post-LT survival, if appropriately revascularized.

2 s underwent angiography, and 2 patients were revascularized.

3 2; P=0.036) compared with those who were not revascularized.

4 Women were also less likely to be revascularized.

5 ejection fractions; and were more completely revascularized.

6 viable myocardium that cannot be adequately revascularized.

7 t (concordant score: 2.93 +/- 0.07), whereas revascularized (0.5 +/- 0.21) and nontreated segments (-

8 Fewer off-pump patients were effectively revascularized (50.1% versus 63.9% on-pump; P<0.001).

9 ate (5.3%) than those with at least 1 lesion revascularized (7.3%) or left untreated despite FFR</=0.

10 4% had a LVEF </=30%; of the 62% of patients revascularized, 77% had a LVEF </=30%.

11 Of the 38% of patients not revascularized, 84% had a LVEF </=30%; of the 62% of pat

12 nts using a limited number of variables (840 revascularized, 840 nonrevascularized), CMR-related reva

13 Of the 11 who were revascularized, 9 (81.8%) had graft salvage and 2 (18.2%

14 The kidney graft, revascularized after 35 min of warm ischemia, also funct

15 ARITY, we showed that embedded islets became revascularized and integrated with the host's vasculatur

16 oth, or a failure if the corneal surface was revascularized and irregular.

17 condary outcomes by transfusion strategy for revascularized and nonrevascularized patients with inter

18 predicting ischemia should the CTO vessel be revascularized and potentially affecting the decision on

19 the renal capsule, we found that islets were revascularized and that the transplant recipient vascula

20 During index hospitalization, 5357 were revascularized, and 4589 were managed without revascular

21 ithin pre-vascularized NICHE were engrafted, revascularized, and functional, reverting diabetes in ra

22 By 7 days, tumors were fully revascularized, and the pericyte phenotype returned to b

23 ftable disease in their other arteries, were revascularized as a primary procedure.

24 were eligible to receive PTCA and CABG were revascularized between 1989 and 1992.

25 te as a main predictor of the patency of the revascularized bioengineered livers (rBELs).

26 rs was 93 +/- 6% in the 24 patients who were revascularized but only 49 +/- 15% in the 34 treated med

27 Of 653 digits that were replanted or revascularized by 65 surgeons, 458 (70.1%) were successf

28 ry territories with significant disease were revascularized by a FitzGibbon A-quality graft to the ma

29 Patients were included if they were revascularized by CABG or PCI-S, had > or = 5 years of f

30 atients with severe ischaemic cardiomyopathy revascularized by either coronary artery bypass grafting

31 ts, tissue grafts such as skin or islets are revascularized by in-growth of host capillaries and ther

32 ic resonance imaging, in patients with STEMI revascularized by primary percutaneous coronary interven

33 value of myocardial viability in surgically revascularized (CABG) patients with left ventricular (LV

34 Consecutive patients with newly revascularized CAD and OSA (apnea-hypopnea index >/=15/h

35 Overall, patient survival in the revascularized CAD group was comparable to angiogram gro

36 transplant, like controls, as were primarily revascularized cardiac allografts.

37 as 46% (78/168) with inducible ischemia were revascularized (coronary bypass surgery, n = 67 or angio

38 atients receiving stents who were completely revascularized (CR) with those who were incompletely rev

39 A successfully revascularized CTO confers a significant 10-year surviva

40 y artery or branch that was not successfully revascularized, divided by the total number of myocardia

41 In total, 609 patients with revascularized first-time STEMI underwent cardiac magnet

42 HAT occurred in 6 of 22 grafts (27.3%) revascularized from the recipient common hepatic artery,

43 nts had a smaller percentage of successfully revascularized index segments than CABG patients (59% ve

44 arized (CR) with those who were incompletely revascularized (IR).

45 ediate benefit may be for the exploration of revascularized islet biology.

46 nsplantation but became a functional part of revascularized islet graft.

47 s from successful animals contained numerous revascularized islets containing a substantial amount of

48 finding associated with angina was a poorly revascularized LAD territory.

49 use death rate was significantly lower among revascularized latecomers (2.1% vs 7.2%; P < 0.001).

50 I: 25.7-35.9) per 1,000 patient-years in the revascularized latecomers group vs 78.7 (95% CI: 67.2-92

51 ful CLI patients (97%) with 266 successfully revascularized limbs revealed that bypass surgery occurr

52 Revascularized liver scaffolds that can maintain blood p

53 The revascularized lung allograft demonstrated a network of

54 Overall, these studies demonstrate that the revascularized lung allograft is responsive to various e

55 the ability of leukocytes to traffic within revascularized lung microvessels by intravital microscop

56 Furthermore, the revascularized microvessels demonstrated the ability to

57 Mean MPRI in revascularized myocardial segments not demonstrating new

58 Five of the 20 patients (25%) were revascularized; of these 5, 2 (40%) had graft salvage, 2

59 ominal wall was removed from the forearm and revascularized on the abdomen (n = 4), or used to close

60 Eleven of 12 patients (91.6%) were revascularized; one patient (8.4%) received no treatment

61 ients with coronary artery disease should be revascularized or treated medically.

62 patients in whom the culprit lesion was not revascularized owing to coronary ostia cannulation failu

63 period, total cardiovascular care costs per revascularized patient decreased by $1680 (95% confidenc

64 hough total cardiovascular-related costs per revascularized patient decreased over this time period,

65 specially in medically treated compared with revascularized patients (100% [8 of 8] vs. 36% [4 of 11]

66 t irrespective of peak troponin levels among revascularized patients (P for interaction=0.004).

67 lative risk, 2.45 [1.58-3.81]) but not among revascularized patients (relative risk, 0.97 [0.59,-1.60

68 his analysis was carried out to determine if revascularized patients derive benefit from the 3-hydrox

69 Among 393,017 revascularized patients followed for a median of 2.7 yea

70 ex hospitalization in 8586 patients (68.0%); revascularized patients had higher peak troponin ratios

71 nts with failed retrograde PCI, successfully revascularized patients showed lower rates of cardiac de

72 Clinical events in revascularized patients were compared between patients o

73 Revascularized patients were more likely to have EF reas

74 ity by race/ethnicity, education, or sex for revascularized patients were observed before or after re

75 Revascularized patients with either percutaneous coronar

76 Revascularized patients with ST-segment-elevation myocar

77 By contrast, in revascularized patients, survival was similar whether my

78 FFR significantly reduced the proportion of revascularized patients, with more patients referred to

79 cause mortality rates may be high in elderly revascularized patients, yet cardiac mortality may be le

80 ss-CMR is more cost-effective in symptomatic revascularized patients.

81 of peak troponin level seem to be minimal in revascularized patients.

82 ival was 84% in nonrevascularized and 95% in revascularized patients.

83 mortality data exist from a large series of revascularized patients.

84 patients with a recent AMI (< or =14 days), revascularized percutaneously, with follow-up of > or =3

85 ic in-stent restenosis and were successfully revascularized percutaneously.

86 Revascularized peripheral artery disease patients face e

87 Pravastatin reduced clinical events in revascularized postinfarction patients with average chol

88 min(-1) . g(-1) . (mm Hg . bpm/10(4))(-1) in revascularized segments and 1.3+/-0.2 mL . min(-1) . g(-

89 Of 109 revascularized segments with severe dysfunction, 46 (42%

90 Of 180 revascularized segments with severe rest dysfunction, re

91 prospective observational study enrolled 451 revascularized ST-elevation myocardial infarction patien

92 currence of medium-term MACE in contemporary revascularized ST-elevation myocardial infarction patien

93 whether ticagrelor maintenance therapy after revascularized ST-segment-elevation myocardial infarctio

94 graft vascular thrombosis (15%, two of three revascularized successfully), bacterial and fungal infec

95 rmed coronary disease were less likely to be revascularized than their male counterparts and were twi

96 gher likelihood of ICD implantation for both revascularized (unadjusted, 12.1% versus 2.4%, P<0.001;

97 myocardial infarction and were successfully revascularized underwent cine and ceMRI of their heart w

98 More coronary targets were able to be revascularized using internal thoracic arteries in patie

99 ed patients rather than for those with fully revascularized viable myocardium.

100 / (baseline BCIS-JS) and RI(myo)= (number of revascularized viable segments) / (number of viable segm

101 anterior-apical wall without the need to be revascularized were enrolled in a prospective, nonrandom

102 outcome after MI, and were less likely to be revascularized when compared with white patients.

103 nsity showed that distorted islets were well revascularized, whereas islets still intact at 1-month p

104 how that decellularized whole porcine livers revascularized with human umbilical vein endothelial cel

105 III) single versus multiple coronary systems revascularized with IMAs (single=490 versus multiple=377

106 ining patent vessel (LRPV), are increasingly revascularized with percutaneous coronary intervention (

107 Patients with IC were predominantly revascularized with stents (IC 48% versus CLI 37%; P<0.0

108 ents were analyzed, of whom 729 (67.7%) were revascularized within 48 hours after hospital admission.

109 e (18 to 24 hours) (201)Tl imaging, were not revascularized within 60 days of SPECT, and were followe